<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Sci Rep</journal-id><journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id><journal-title-group><journal-title>Scientific Reports</journal-title></journal-title-group><issn pub-type="epub">2045-2322</issn><publisher><publisher-name>Nature Publishing Group UK</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28273894</article-id><article-id pub-id-type="pmc">5427966</article-id><article-id pub-id-type="publisher-id">224</article-id><article-id pub-id-type="doi">10.1038/s41598-017-00224-6</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Six-month efficacy of platelet-rich plasma for carpal tunnel syndrome: A prospective randomized, single-blind controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Yung-Tsan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Ho</surname><given-names>Tsung-Yen</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Chou</surname><given-names>Yu-Ching</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Ke</surname><given-names>Ming-Jen</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Tsung-Ying</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Guo-Shu</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Chen</surname><given-names>Liang-Cheng</given-names></name><address><email>clctsgh@yahoo.com.tw</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label>Department of Physical Medicine and Rehabilitation, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, No. 325, Sec. 2, Cheng-Kung Road, Neihu District, Taipei, Taiwan Republic of China </aff><aff id="Aff2"><label>2</label>Integrated Pain Management Center, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, No. 325, Sec. 2, Cheng-Kung Road, Neihu District, Taipei, Taiwan Republic of China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0634 0356</institution-id><institution-id institution-id-type="GRID">grid.260565.2</institution-id><institution>School of Public Health, </institution><institution>National Defense Medical Center, </institution></institution-wrap>No. 161, Sec. 6, Minquan East Road, Neihu District, Taipei, Taiwan Republic of China </aff><aff id="Aff4"><label>4</label>Department of Radiology, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, No. 325, Sec. 2, Cheng-Kung Road, Neihu District, Taipei, Taiwan Republic of China </aff></contrib-group><pub-date pub-type="epub"><day>7</day><month>3</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>7</day><month>3</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>7</volume><elocation-id>94</elocation-id><history><date date-type="received"><day>3</day><month>11</month><year>2016</year></date><date date-type="accepted"><day>14</day><month>2</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2017</copyright-statement><license license-type="OpenAccess"><license-p>This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article&#x02019;s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>
</license-p></license></permissions><abstract id="Abs1"><p>Recently, a few small reports with short follow-up period have shown clinical benefits of platelet-rich plasma (PRP) for peripheral neuropathy including one pilot study and one small, non-randomized trial in patients with carpal tunnel syndrome (CTS). Therefore, we conducted a randomized, single-blind, controlled trial to assess the 6-month effect of PRP in patients with CTS. Sixty patients with unilateral mild-to-moderate CTS were randomized into two groups of 30, namely the PRP and control groups. In the PRP group, patients were injected with one dose of 3&#x02009;mL of PRP using ultrasound guidance and the control group received a night splint through the study period. The primary outcome measure was the visual analog scale (VAS) and secondary outcome measures included the Boston Carpal Tunnel Syndrome Questionnaire (BCTQ) score, the cross-sectional area (CSA) of the median nerve (MN), electrophysiological findings of the MN, and finger pinch strength. The evaluation was performed before treatment and at 1, 3, and 6 months post-injection. The PRP group exhibited a significant reduction in the VAS score, BCTQ score, and CSA of MN compared to the those of control group 6 months post-treatment (p&#x02009;&#x0003c;&#x02009;0.05). Our study demonstrates that PRP is a safe modality that effectively relieves pain and improves disability in the patients with CTS.</p></abstract><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p>Carpal tunnel syndrome (CTS) is the most common peripheral entrapment neuropathy. The gradual ischemia resulting from high pressure with accompanying compression of the median nerve (MN) within the carpal tunnel is thought to contribute to the pathophysiology of CTS<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. Moreover, CTS can cause inflammation of the intracarpal tendon including the flexor pollicis longus, deep and superficial flexor tendons. The inflammation of the tendon frequently produces a cycle of intracarpal swelling causing further compression of MN<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>. Typical symptoms and signs include numbness, tingling, pain, or burning sensation in the digits controlled by the MN, and/or nocturnal paresthesia. Thenar muscle wasting might also occur during the chronic stages<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>.</p><p>Treatments for CTS range from conservative strategies (medication, night splint, steroid injections, and physical therapy) to surgical decompression of the MN. Despite the availability of conservative therapies, their efficacy is usually unfavorable or short-lived<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>. A report revealed that approximately 60 to 70% patients with CTS who underwent conservative treatment still had symptoms after 18 months&#x02019; follow-up<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>. Moreover, a recent study has shown that the treatment failure rate of the wrist splint was reported as 69% after 12 months&#x02019; follow-up<sup><xref ref-type="bibr" rid="CR5">5</xref></sup>. Although surgical intervention is more effective than conservative treatment, conservative therapies are advocated for mild-to-moderate CTS. Surgical therapy is suggested for severe CTS or patients with poor response to conservative treatments, since the failure rate of surgery ranges from 7&#x02013;75%<sup><xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref></sup>. Therefore, it is important to explore and develop a novel non-surgical intervention for CTS.</p><p>Platelet-rich plasma (PRP) is a biologic product of concentrated platelets and contains several growth factors that promote wound healing/growth, angiogenesis, and axon regeneration. PRP has been widely used as a safe and novel treatment in dentistry, orthopedics, ophthalmology, neurosurgery, and cosmetic surgery for three decades<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>. Recently, increasing evidence has revealed the beneficial effects of PRP on axon regeneration and neurological recovery in animal or <italic>vitro</italic> studies<sup><xref ref-type="bibr" rid="CR9">9</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref></sup>. Since 2014, a few studies have applied PRP for treating clinical peripheral neuropathy, with acceptable success rates<sup><xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref></sup>. Among these studies, there was one pilot study and one small, non-randomized trial enrolling patients with CTS. It would be helpful to examine whether PRP aids in the promotion of extensive axon regeneration in the human population. However, the definite clinical effects of PRP on peripheral neuropathy are unclear due to small population sizes and short follow-up periods in published reports. This points to the need for a well-designed study to evaluate the effects of PRP on clinical regeneration following peripheral nerve injury.</p><p>In the present study, we investigated the 6-month effects of PRP in patients with mild-to-moderate CTS.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study design</title><p>This study was designed according to the CONSORT 2010 statement<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>. This prospective, randomized, single-blinded, controlled study was conducted at Tri-Service General Hospital, Taiwan from November 2015 to October 2016. The study protocol was reviewed and approved by the Institutional Review Board of Tri-Service General Hospital (No. 1-104-05-108). All enrolled patients provided written, informed consent for the study. The study was performed in accordance with the principles of Declaration of Helsinki. The study was registered at <ext-link ext-link-type="uri" xlink:href="http://www.ClinicalTrials.gov">www.ClinicalTrials.gov</ext-link> (number NCT02539186) on 8/31/2015. All methods for each subject were performed in accordance with the approved ethical guideline and there were no changes made to this trial after the commencement of the recruitment.</p><p>Eighty patients diagnosed with mild-to-moderate unilateral CTS were assessed for eligibility, and 60 were enrolled. The enrolled patients were block randomized in a 1:1 ratio into two groups, control and PRP groups, by an independent researcher via computer-generated randomization of study numbers (Microsoft Excel, Microsoft Inc., Redmond, WA, USA). The PRP group received one dose of ultrasound-guided PRP injection, while the control group wore a wrist splint. The splint was applied in a neutral position to restrict the wrist as previously described<sup><xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR23">23</xref></sup>. The controls were instructed to put on the splint overnight for at least 8&#x02009;hours daily throughout the study period. All participants were instructed to refrain from any other management approaches for symptoms resulting from CTS such as analgesics, steroid injections, or physical therapy, from 2 weeks before and throughout the study period, and were requested to report receiving any of these therapies.</p></sec><sec id="Sec4"><title>Inclusion and exclusion criteria</title><p>Participants diagnosed with mild-to-moderate unilateral CTS with clinical symptoms for at least 3 months undergoing electrophysiological study and ultrasonography were enrolled. The clinical symptoms and signs for the diagnosis of CTS were summarized in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. If the patients met criterion 1 and one or more of criteria 2&#x02013;4, the clinical diagnosis of CTS was established<sup><xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref></sup>.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Summarization of inclusion and exclusion criteria.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Inclusion criteria of symptoms and signs</th></tr></thead><tbody><tr><td>1. Paresthesia/dysesthesia, painful swelling with clumsy weakness of the hand exacerbated by sleep or repetitive use of the wrist, and relieved by shaking the hand with postural change.</td></tr><tr><td>2. Sensory loss with numbness in the median nerve-innervated regions of the hand.</td></tr><tr><td>3. Weakness with atrophy of the median nerve-innervated thenar muscles.</td></tr><tr><td>4. Positive Phalen&#x02019;s test and/or Tinel&#x02019;s sign.</td></tr><tr><td>
<bold>Exclusion criteria</bold>
</td></tr><tr><td>1. History of wrist surgery, polyneuropathy, brachial plexopathy, or thoracic outlet syndrome.</td></tr><tr><td>2. History of thrombocytopenia, platelet dysfunction, systematic infection, pregnancy, and rheumatologic disorders.</td></tr><tr><td>3. Previous steroid injection for carpal tunnel syndrome.</td></tr></tbody></table></table-wrap>
</p><p>The cut-off points or normal range of the electrophysiological study for CTS in this study were as follows: (1) upper limit of the median sensory nerve distal latency is &#x02264;3.6&#x02009;ms at a distance 14&#x02009;cm away from the active recording; (2) difference in distal latencies between the ulnar and median sensory nerve is &#x0003c;0.4&#x02009;ms; and (3) upper limit of distal motor latency (DML) of the MN is &#x0003c;4.3&#x02009;ms at a distance 8&#x02009;cm away from the thenar muscle belly<sup><xref ref-type="bibr" rid="CR26">26</xref>&#x02013;<xref ref-type="bibr" rid="CR28">28</xref></sup>. Patients were excluded if they met one of the exclusion criteria (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>).</p></sec><sec id="Sec5"><title>Grades of CTS</title><p>Patients with mild and moderate CTS were categorized by the electrophysiological classification of CTS by Padua <italic>et al</italic>.<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>: mild: only abnormal digit/wrist sensory nerve conduction velocity (SNCV) with normal DML; moderate: abnormal digit/wrist SNCV and abnormal DML; or severe: absence of SNCV and abnormal DML.</p></sec><sec id="Sec6"><title>PRP preparation</title><p>Ten milliliters of blood sample were drawn from the antercubital vein using RegentKit-THT-1 (RegenLab SA, Mont-sur-Lausanne, Switzerland) followed by centrifugation at 3400&#x02009;rpm for 15&#x02009;minutes at room temperature using Regen Lab PRP Centri, yielding 3.5&#x02009;mL of PRP<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>. The RegentKit-THT-1 has sodium citrate solution as an anticoagulant, and autologous thrombin as an activator to advance platelet activation and conversion of fibrinogen to fibrin. For quality tests, 0.5&#x02009;mL of the PRP sample was sent to the laboratory and 3&#x02009;mL was used for the ultrasound-guided injection. The concentration of platelets and leukocytes in the PRP was approximately 2.7&#x02009;&#x000b1;&#x02009;0.4 times and 1.2&#x02009;&#x000b1;&#x02009;0.4 times compared to that in whole blood, respectively.</p></sec><sec id="Sec7"><title>Ultrasound-guided PRP injection</title><p>The ultrasound-guided PRP injection was performed by the same physiatrist (Dr. Wu), using ultrasonography (MyLab&#x02122; 25Gold, Esaote, Genova, Italy). With the palm facing upwards and the wrist slightly extended, the MN was identified at the inlet of the proximal carpal tunnel (pisiform level)<sup><xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref></sup>. The ultrasound-guided injection was conducted using the in-plane ulnar approach<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>. The ulnar artery was identified using Doppler imaging, and a 25-gauge needle was passed from the ulnar side of the wrist toward the MN. After placing the needle tip on the MN, 2&#x02009;mL of PRP was injected to peel the nerve off the flexor retinaculum via hydrodissection (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1a</xref>). An additional 1&#x02009;mL of PRP was delivered to the inferior part of the MN and the MN was peeled from the underlying subsynovial connective tissue (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1b</xref>). After this, the entire carpal tunnel was scanned to ensure that the PRP had spread throughout the proximal-to-distal area of the carpal tunnel (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1c</xref>). All patients were observed for 10&#x02009;minutes after injection for possible dysesthesia or bleeding.<fig id="Fig1"><label>Figure 1</label><caption><p>Ultrasonographic imaging. (<bold>a</bold>) Transverse view showing the median nerve (MN) peeled off from the flexor retinaculum (arrows) using 2&#x02009;mL of PRP via hydrodissection (asterisk). (<bold>b</bold>) Transverse view showing the MN separated from the inferior underlying subsynovial connective tissue using an additional 1&#x02009;mL of PRP via hydrodissection (asterisk). (<bold>c</bold>) Long axial view showing the distribution of PRP throughout the proximal-to-distal area of the carpal tunnel (asterisk). MN: median nerve; FPL: flexor pollicis longus; FDS: flexor digitorum superficialis; FDP: flexor digitorum profundus.</p></caption><graphic xlink:href="41598_2017_224_Fig1_HTML" id="d29e478"/></fig>
</p></sec><sec id="Sec8"><title>Outcome measurements</title><p>One physiatrist (Dr. Ke) with 5 years&#x02019; experience in musculoskeletal ultrasonography and electrophysiological study, who was blinded to the patients&#x02019; randomization, performed all the measurements in all patients of both groups before intervention and at months 1, 3, and 6 after treatment.</p></sec><sec id="Sec9"><title>Primary outcomes</title><sec id="Sec10"><title>Visual analog scale (VAS)</title><p>Digital pain severity and paresthesia within 7 days of the assessment were measured using the VAS, with 10 points indicating extremely severe pain and 0 points indicating no pain<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>.</p></sec></sec><sec id="Sec11"><title>Secondary outcomes</title><sec id="Sec12"><title>1. Boston Carpal Tunnel Syndrome Questionnaire (BCTQ)</title><p>BCTQ was employed to evaluate the severity of symptoms and functional status with reproducibility, internal consistency, and validity for patients with CTS<sup><xref ref-type="bibr" rid="CR34">34</xref></sup>. The subscale of symptom severity consists of 11 questions and the scores range from 1&#x02013;5 points. The functional status subscale has 8 questions, and scores range from 1&#x02013;5 points; higher scores mean worse severity and dysfunction.</p></sec><sec id="Sec13"><title>2. Cross-sectional area (CSA) of MN</title><p>CSA of the MN was evaluated as previously described<sup><xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR30">30</xref></sup>. In brief, CSA was measured with an electronic caliper at the proximal inlet of the carpal tunnel using the pisiform bone as a landmark. The average of CSA was calculated using three measurements each.</p></sec><sec id="Sec14"><title>3. Electrophysiological study</title><p>The antidromic SNCV and DML of the MN were measured in all patients by using SierraWave, Cadwell (USA)<sup><xref ref-type="bibr" rid="CR35">35</xref></sup>. The antidromic SNCV was examined as described in our previous study<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>. The DML was recorded via MN stimulation 8&#x02009;cm proximal to the active electrode over the abductor pollicis brevis muscle. The average of SNCV and DML were calculated using three measurements each.</p></sec><sec id="Sec15"><title>4. Finger pinch (FP)</title><p>The palmar FP force was detected with a Jamar dynamometer (Fabrication Enterprises Inc., USA) as described in our previous study<sup><xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR36">36</xref></sup>. The average of three test values was used for statistical analysis.</p></sec></sec><sec id="Sec16"><title>Sample size</title><p>To reduce type II errors and increase the power, a preliminary power analysis using G* power 3.1.9.2 (UCLA, Los Angeles, CA, USA) [power (1-&#x003b2;)&#x02009;=&#x02009;0.9; &#x003b1;&#x02009;=&#x02009;0.05; effect size&#x02009;=&#x02009;0.45] indicated that a sample of 54 people was required<sup><xref ref-type="bibr" rid="CR37">37</xref></sup>.</p></sec><sec id="Sec17"><title>Data analysis</title><p>Statistical analyses were conducted with IBM SPSS Statistics Version 22. Demographic statistics were analyzed using the independent t-test for continuous data and X<sup>2</sup> test for categorical data. The repeated-measures ANOVA followed by post hoc tests was performed for the data at various follow-ups. The independent t-test was used to compare the differences between the groups. All statistical tests were two-tailed and a p-value less than 0.05 was considered as statistically significant.</p></sec></sec><sec id="Sec18" sec-type="results"><title>Results</title><p>All 60 participants completed the study and 30 wrists in each study group were analyzed (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). The clinical characteristics of participants are summarized in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>, and there were no significant differences in the variables between two groups. More than 80% of the patients were graded as having moderate CTS. Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref> shows the VAS scores, BCTQ scores, electrophysiological study, CSA of the MN, and FP before and after treatment. Comparing the baseline data, a significant improvement in all outcome measures was observed in the PRP and control groups at all follow-up assessments (p&#x02009;&#x0003c;&#x02009;0.05) (not including the 1<sup>st</sup> month FP in the control group, p&#x02009;=&#x02009;0.071).<fig id="Fig2"><label>Figure 2</label><caption><p>Study flow diagram<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>.</p></caption><graphic xlink:href="41598_2017_224_Fig2_HTML" id="d29e592"/></fig>
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Baseline demographic and clinical characteristics of study participants.</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>PRP group (n&#x02009;=&#x02009;30)</th><th>Control group (n&#x02009;=&#x02009;30)</th><th>
<italic>p</italic> value</th></tr></thead><tbody><tr><td>Age (year) (SE)</td><td>57.87&#x02009;&#x000b1;&#x02009;1.51</td><td>54.27&#x02009;&#x000b1;&#x02009;1.34</td><td>0.08</td></tr><tr><td>Body height (cm)</td><td>154.80&#x02009;&#x000b1;&#x02009;0.63</td><td>156.57&#x02009;&#x000b1;&#x02009;1.19</td><td>0.197</td></tr><tr><td>Body weight (kg)</td><td>62.23&#x02009;&#x000b1;&#x02009;1.28</td><td>62.13&#x02009;&#x000b1;&#x02009;2.33</td><td>0.97</td></tr><tr><td>Diabetes mellitus (n)</td><td>4 (13.33)</td><td>3 (10.00)</td><td>1.000</td></tr><tr><td>Hypertension (n)</td><td>9 (30.00)</td><td>11 (36.67)</td><td>0.784</td></tr><tr><td>Sex</td><td/><td/><td>0.706</td></tr><tr><td>&#x000a0;Male (n) (%)</td><td>3 (10.00)</td><td>5 (16.67)</td><td/></tr><tr><td>&#x000a0;Female (n) (%)</td><td>27 (90.00)</td><td>25 (83.33)</td><td/></tr><tr><td>Duration (months) (SE)</td><td>34.43&#x02009;&#x000b1;&#x02009;5.67</td><td>30.70&#x02009;&#x000b1;&#x02009;6.03</td><td>0.654</td></tr><tr><td>Dominant hand</td><td/><td/><td>&#x02014;</td></tr><tr><td>&#x000a0;Right (n) (%)</td><td>30 (100%)</td><td>30 (100%)</td><td/></tr><tr><td>&#x000a0;Left (n) (%)</td><td>0 (0)</td><td>0 (0)</td><td/></tr><tr><td>Lesion site</td><td/><td/><td>0.796</td></tr><tr><td>&#x000a0;Right (n) (%)</td><td>15 (50.00)</td><td>17 (56.67)</td><td/></tr><tr><td>&#x000a0;Left (n) (%)</td><td>15 (50.00)</td><td>13 (43.33)</td><td/></tr><tr><td>Grading (Padua)</td><td/><td/><td>1.000</td></tr><tr><td>&#x000a0;Moderate</td><td>25 (83.33)</td><td>26 (86.67)</td><td/></tr><tr><td>&#x000a0;Mild</td><td>5 (16.67)</td><td>4 (13.33)</td><td/></tr><tr><td>VAS</td><td>6.50&#x02009;&#x000b1;&#x02009;0.30</td><td>6.29&#x02009;&#x000b1;&#x02009;0.31</td><td>0.631</td></tr><tr><td>BCTQs</td><td>26.17&#x02009;&#x000b1;&#x02009;1.10</td><td>24.93&#x02009;&#x000b1;&#x02009;1.22</td><td>0.457</td></tr><tr><td>BCTQf</td><td>19.23&#x02009;&#x000b1;&#x02009;1.08</td><td>18.13&#x02009;&#x000b1;&#x02009;0.65</td><td>0.387</td></tr><tr><td>FP (kg)</td><td>3.27&#x02009;&#x000b1;&#x02009;0.28</td><td>3.74&#x02009;&#x000b1;&#x02009;0.11</td><td>0.133</td></tr><tr><td>SNCV (m/s)</td><td>30.18&#x02009;&#x000b1;&#x02009;1.29</td><td>32.35&#x02009;&#x000b1;&#x02009;1.10</td><td>0.205</td></tr><tr><td>DML (ms)</td><td>5.66&#x02009;&#x000b1;&#x02009;0.27</td><td>5.21&#x02009;&#x000b1;&#x02009;0.23</td><td>0.215</td></tr><tr><td>CSA (mm<sup>2</sup>)</td><td>14.01&#x02009;&#x000b1;&#x02009;0.82</td><td>12.91&#x02009;&#x000b1;&#x02009;0.81</td><td>0.343</td></tr></tbody></table><table-wrap-foot><p>SE&#x02009;=&#x02009;Standard error; VAS&#x02009;=&#x02009;Visual analog scale; BCTQ&#x02009;=&#x02009;Boston Carpal Tunnel Syndrome Questionnaire (s&#x02009;=&#x02009;severity and f&#x02009;=&#x02009;function); FP&#x02009;=&#x02009;Finger pinch; SNCV&#x02009;=&#x02009;Sensory nerve conduction velocity; DML&#x02009;=&#x02009;Distal motor latency; CSA&#x02009;=&#x02009;Cross-sectional area.</p></table-wrap-foot></table-wrap>
<table-wrap id="Tab3"><label>Table 3</label><caption><p>All the Outcome variables in each group before and after treatment.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th colspan="2">PRP group (n&#x02009;=&#x02009;30)</th><th colspan="2">Control group (n&#x02009;=&#x02009;30)</th></tr><tr><th>Mean&#x02009;&#x000b1;&#x02009;SE</th><th>
<italic>p</italic> value</th><th>Mean&#x02009;&#x000b1;&#x02009;SE</th><th>
<italic>p</italic> value</th></tr></thead><tbody><tr><td>VAS-Pre</td><td>6.50&#x02009;&#x000b1;&#x02009;0.30</td><td/><td>6.29&#x02009;&#x000b1;&#x02009;0.31</td><td/></tr><tr><td>&#x000a0;VAS month 1</td><td>3.89&#x02009;&#x000b1;&#x02009;0.28</td><td>&#x0003c;0.001</td><td>3.88&#x02009;&#x000b1;&#x02009;0.28</td><td>&#x0003c;0.001</td></tr><tr><td>&#x000a0;VAS month 3</td><td>2.91&#x02009;&#x000b1;&#x02009;0.23</td><td>&#x0003c;0.001</td><td>3.36&#x02009;&#x000b1;&#x02009;0.26</td><td>&#x0003c;0.001</td></tr><tr><td>&#x000a0;VAS month 6</td><td>1.97&#x02009;&#x000b1;&#x02009;0.23</td><td>&#x0003c;0.001</td><td>2.99&#x02009;&#x000b1;&#x02009;0.27</td><td>&#x0003c;0.001</td></tr><tr><td>BCTQs-Pre</td><td>26.17&#x02009;&#x000b1;&#x02009;1.10</td><td/><td>24.93&#x02009;&#x000b1;&#x02009;1.22</td><td/></tr><tr><td>&#x000a0;BCTQs month 1</td><td>17.17&#x02009;&#x000b1;&#x02009;0.63</td><td>&#x0003c;0.001</td><td>18.43&#x02009;&#x000b1;&#x02009;0.93</td><td>&#x0003c;0.001</td></tr><tr><td>&#x000a0;BCTQs month 3</td><td>15.76&#x02009;&#x000b1;&#x02009;0.50</td><td>&#x0003c;0.001</td><td>18.13&#x02009;&#x000b1;&#x02009;1.02</td><td>&#x0003c;0.001</td></tr><tr><td>&#x000a0;BCTQs month 6</td><td>14.14&#x02009;&#x000b1;&#x02009;0.45</td><td>&#x0003c;0.001</td><td>16.20&#x02009;&#x000b1;&#x02009;0.86</td><td>&#x0003c;0.001</td></tr><tr><td>BCTQf-Pre</td><td>19.23&#x02009;&#x000b1;&#x02009;1.08</td><td/><td>18.13&#x02009;&#x000b1;&#x02009;0.65</td><td/></tr><tr><td>&#x000a0;BCTQf month 1</td><td>12.24&#x02009;&#x000b1;&#x02009;0.55</td><td>&#x0003c;0.001</td><td>14.40&#x02009;&#x000b1;&#x02009;0.70</td><td>0.001</td></tr><tr><td>&#x000a0;BCTQf month 3</td><td>10.79&#x02009;&#x000b1;&#x02009;0.40</td><td>&#x0003c;0.001</td><td>13.63&#x02009;&#x000b1;&#x02009;0.66</td><td>&#x0003c;0.001</td></tr><tr><td>&#x000a0;BCTQf month 6</td><td>10.41&#x02009;&#x000b1;&#x02009;0.48</td><td>&#x0003c;0.001</td><td>12.93&#x02009;&#x000b1;&#x02009;0.65</td><td>&#x0003c;0.001</td></tr><tr><td>FP-Pre (kg)</td><td>3.27&#x02009;&#x000b1;&#x02009;0.28</td><td/><td>3.74&#x02009;&#x000b1;&#x02009;0.11</td><td/></tr><tr><td>&#x000a0;FP month 1</td><td>4.06&#x02009;&#x000b1;&#x02009;0.27</td><td>0.002</td><td>4.26&#x02009;&#x000b1;&#x02009;0.18</td><td>0.071</td></tr><tr><td>&#x000a0;FP month 3</td><td>4.13&#x02009;&#x000b1;&#x02009;0.29</td><td>&#x0003c;0.001</td><td>4.22&#x02009;&#x000b1;&#x02009;0.17</td><td>0.040</td></tr><tr><td>&#x000a0;FP month 6</td><td>4.45&#x02009;&#x000b1;&#x02009;0.23</td><td>&#x0003c;0.001</td><td>4.68&#x02009;&#x000b1;&#x02009;0.23</td><td>0.001</td></tr><tr><td>SNCV-Pre (m/s)</td><td>30.18&#x02009;&#x000b1;&#x02009;1.29</td><td/><td>32.35&#x02009;&#x000b1;&#x02009;1.10</td><td/></tr><tr><td>&#x000a0;SNCV month 1</td><td>32.45&#x02009;&#x000b1;&#x02009;1.25</td><td>&#x0003c;0.001</td><td>34.74&#x02009;&#x000b1;&#x02009;1.21</td><td>&#x0003c;0.001</td></tr><tr><td>&#x000a0;SNCV month 3</td><td>32.82&#x02009;&#x000b1;&#x02009;1.27</td><td>&#x0003c;0.001</td><td>35.05&#x02009;&#x000b1;&#x02009;1.28</td><td>&#x0003c;0.001</td></tr><tr><td>&#x000a0;SNCV month 6</td><td>33.92&#x02009;&#x000b1;&#x02009;1.34</td><td>&#x0003c;0.001</td><td>36.17&#x02009;&#x000b1;&#x02009;1.34</td><td>&#x0003c;0.001</td></tr><tr><td>DML-Pre (ms)</td><td>5.66&#x02009;&#x000b1;&#x02009;0.27</td><td/><td>5.21&#x02009;&#x000b1;&#x02009;0.23</td><td/></tr><tr><td>&#x000a0;DML month 1</td><td>5.28&#x02009;&#x000b1;&#x02009;0.23</td><td>&#x0003c;0.001</td><td>4.96&#x02009;&#x000b1;&#x02009;0.22</td><td>0.041</td></tr><tr><td>&#x000a0;DML month 3</td><td>5.26&#x02009;&#x000b1;&#x02009;0.25</td><td>0.006</td><td>4.98&#x02009;&#x000b1;&#x02009;0.22</td><td>0.016</td></tr><tr><td>&#x000a0;DML month 6</td><td>5.18&#x02009;&#x000b1;&#x02009;0.26</td><td>0.001</td><td>4.74&#x02009;&#x000b1;&#x02009;0.19</td><td>&#x0003c;0.001</td></tr><tr><td>CSA-Pre (mm<sup>2</sup>)</td><td>14.01&#x02009;&#x000b1;&#x02009;0.82</td><td/><td>12.91&#x02009;&#x000b1;&#x02009;0.81</td><td/></tr><tr><td>&#x000a0;CSA month 1</td><td>11.86&#x02009;&#x000b1;&#x02009;0.76</td><td>&#x0003c;0.001</td><td>11.72&#x02009;&#x000b1;&#x02009;0.81</td><td>&#x0003c;0.001</td></tr><tr><td>&#x000a0;CSA month 3</td><td>11.35&#x02009;&#x000b1;&#x02009;0.74</td><td>&#x0003c;0.001</td><td>11.23&#x02009;&#x000b1;&#x02009;0.72</td><td>&#x0003c;0.001</td></tr><tr><td>&#x000a0;CSA month 6</td><td>10.93&#x02009;&#x000b1;&#x02009;0.75</td><td>&#x0003c;0.001</td><td>10.87&#x02009;&#x000b1;&#x02009;0.76</td><td>&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><p>SE&#x02009;=&#x02009;Standard error; VAS&#x02009;=&#x02009;Visual analog scale; BCTQ&#x02009;=&#x02009;Boston Carpal Tunnel Syndrome Questionnaire (s&#x02009;=&#x02009;severity and f&#x02009;=&#x02009;function); FP&#x02009;=&#x02009;Finger pinch; SNCV&#x02009;=&#x02009;Sensory nerve conduction velocity; DML&#x02009;=&#x02009;Distal motor latency; CSA&#x02009;=&#x02009;Cross-sectional area; Pre&#x02009;=&#x02009;Pretreatment.</p></table-wrap-foot></table-wrap>
</p><p>Comparing the two groups, there was significantly greater enhancement in the PRP group at all follow-up time points in the VAS scores, BCTQ scores, and CSA of the MN (except for the 1<sup>st</sup> and 3<sup>rd</sup> month VAS score and 1<sup>st</sup> month BCTQ-severity score) and this tendency became more pronounced as the follow-up duration increased (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>, Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref> and <xref rid="Fig4" ref-type="fig">4</xref>). Although a tendency towards increased FP with a longer follow-up period was found in the PRP group compared with the control group, the difference was not statistically significant (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>). The difference in SNCV and DML between the two groups was not statistically significant at all follow-up assessments (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>). No side-effects or nerve trauma were observed in either of the two groups. All patients reported taking no additional medicine or receiving other therapies throughout the study.<table-wrap id="Tab4"><label>Table 4</label><caption><p>Changes of outcome variables from baseline at 1, 3 and 6 month in the PRP group compared with the control group.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th>PRP group (n&#x02009;=&#x02009;30)</th><th>Control group (n&#x02009;=&#x02009;30)</th><th rowspan="2">
<italic>p</italic> value</th></tr><tr><th>Mean difference&#x02009;&#x000b1;&#x02009;SE</th><th>Mean difference&#x02009;&#x000b1;&#x02009;SE</th></tr></thead><tbody><tr><td colspan="4">VAS-Pre</td></tr><tr><td>&#x000a0;VAS month 1</td><td>&#x02212;2.61&#x02009;&#x000b1;&#x02009;0.26</td><td>&#x02212;2.41&#x02009;&#x000b1;&#x02009;0.20</td><td>0.540</td></tr><tr><td>&#x000a0;VAS month 3</td><td>&#x02212;3.59&#x02009;&#x000b1;&#x02009;0.34</td><td>&#x02212;2.93&#x02009;&#x000b1;&#x02009;0.20</td><td>0.104</td></tr><tr><td>&#x000a0;VAS month 6</td><td>&#x02212;4.53&#x02009;&#x000b1;&#x02009;0.37</td><td>&#x02212;3.30&#x02009;&#x000b1;&#x02009;0.34</td><td>0.018</td></tr><tr><td colspan="4">BCTQs-Pre</td></tr><tr><td>&#x000a0;BCTQs month 1</td><td>&#x02212;8.93&#x02009;&#x000b1;&#x02009;1.10</td><td>&#x02212;6.50&#x02009;&#x000b1;&#x02009;0.94</td><td>0.098</td></tr><tr><td>&#x000a0;BCTQs month 3</td><td>&#x02212;10.47&#x02009;&#x000b1;&#x02009;1.17</td><td>&#x02212;6.80&#x02009;&#x000b1;&#x02009;0.93</td><td>0.017</td></tr><tr><td>&#x000a0;BCTQs month 6</td><td>&#x02212;11.76&#x02009;&#x000b1;&#x02009;1.21</td><td>&#x02212;8.73&#x02009;&#x000b1;&#x02009;0.85</td><td>0.045</td></tr><tr><td colspan="4">BCTQf-Pre</td></tr><tr><td>&#x000a0;BCTQf month 1</td><td>&#x02212;7.00&#x02009;&#x000b1;&#x02009;0.88</td><td>&#x02212;3.73&#x02009;&#x000b1;&#x02009;0.49</td><td>0.002</td></tr><tr><td>&#x000a0;BCTQf month 3</td><td>&#x02212;8.37&#x02009;&#x000b1;&#x02009;0.87</td><td>&#x02212;4.50&#x02009;&#x000b1;&#x02009;0.50</td><td>&#x0003c;0.001</td></tr><tr><td>&#x000a0;BCTQf month 6</td><td>&#x02212;8.72&#x02009;&#x000b1;&#x02009;0.86</td><td>&#x02212;5.20&#x02009;&#x000b1;&#x02009;0.46</td><td>0.001</td></tr><tr><td colspan="4">FP-Pre (kg)</td></tr><tr><td>&#x000a0;FP month 1</td><td>0.74&#x02009;&#x000b1;&#x02009;0.16</td><td>0.53&#x02009;&#x000b1;&#x02009;0.17</td><td>0.384</td></tr><tr><td>&#x000a0;FP month 3</td><td>0.81&#x02009;&#x000b1;&#x02009;0.15</td><td>0.49&#x02009;&#x000b1;&#x02009;0.15</td><td>0.138</td></tr><tr><td>&#x000a0;FP month 6</td><td>1.12&#x02009;&#x000b1;&#x02009;0.15</td><td>0.95&#x02009;&#x000b1;&#x02009;0.20</td><td>0.482</td></tr><tr><td colspan="4">SNCV-Pre (m/s)</td></tr><tr><td>&#x000a0;SNCV month 1</td><td>2.26&#x02009;&#x000b1;&#x02009;0.18</td><td>2.39&#x02009;&#x000b1;&#x02009;0.41</td><td>0.779</td></tr><tr><td>&#x000a0;SNCV month 3</td><td>2.64&#x02009;&#x000b1;&#x02009;0.40</td><td>2.70&#x02009;&#x000b1;&#x02009;0.39</td><td>0.917</td></tr><tr><td>&#x000a0;SNCV month 6</td><td>3.74&#x02009;&#x000b1;&#x02009;0.60 </td><td>3.81&#x02009;&#x000b1;&#x02009;0.54</td><td>0.925</td></tr><tr><td colspan="4">DML-Pre (ms)</td></tr><tr><td>&#x000a0;DML month 1</td><td>&#x02212;0.38&#x02009;&#x000b1;&#x02009;0.07</td><td>&#x02212;0.25&#x02009;&#x000b1;&#x02009;0.08</td><td>0.199</td></tr><tr><td>&#x000a0;DML month 3</td><td>&#x02212;0.40&#x02009;&#x000b1;&#x02009;0.10</td><td>&#x02212;0.23&#x02009;&#x000b1;&#x02009;0.06</td><td>0.157</td></tr><tr><td>&#x000a0;DML month 6</td><td>&#x02212;0.48&#x02009;&#x000b1;&#x02009;0.10</td><td>&#x02212;0.47&#x02009;&#x000b1;&#x02009;0.08</td><td>0.934</td></tr><tr><td colspan="4">CSA-Pre (mm<sup>2</sup>)</td></tr><tr><td>&#x000a0;CSA month 1</td><td>&#x02212;2.15&#x02009;&#x000b1;&#x02009;0.24</td><td>&#x02212;1.19&#x02009;&#x000b1;&#x02009;0.21</td><td>0.004</td></tr><tr><td>&#x000a0;CSA month 3</td><td>&#x02212;2.66&#x02009;&#x000b1;&#x02009;0.19</td><td>&#x02212;1.68&#x02009;&#x000b1;&#x02009;0.25</td><td>0.003</td></tr><tr><td>&#x000a0;CSA month 6</td><td>&#x02212;3.08&#x02009;&#x000b1;&#x02009;0.20</td><td>&#x02212;2.04&#x02009;&#x000b1;&#x02009;0.28</td><td>0.004</td></tr></tbody></table><table-wrap-foot><p>VAS&#x02009;=&#x02009;Visual analog scale; BCTQ&#x02009;=&#x02009;Boston Carpal Tunnel Syndrome Questionnaire (s&#x02009;=&#x02009;severity and f&#x02009;=&#x02009;function); FP&#x02009;=&#x02009;Finger pinch; SNCV&#x02009;=&#x02009;Sensory nerve conduction velocity; DML&#x02009;=&#x02009;Distal motor latency; CSA&#x02009;=&#x02009;Cross-sectional are; Pre&#x02009;=&#x02009;Pretreatment; SE&#x02009;=&#x02009;Standard error.</p></table-wrap-foot></table-wrap>
<fig id="Fig3"><label>Figure 3</label><caption><p>Mean change from baseline in visual analog scale (VAS) and cross-sectional area (CSA) of medain nerve (MN) in both groups (mean&#x02009;&#x000b1;&#x02009;standard error). (<bold>A</bold>) PRP group had significant improvement of VAS compared with control group at 6<sup>th</sup> month (p&#x02009;&#x0003c;&#x02009;0.05). (<bold>B</bold>) PRP group had significant improvement of CSA compared with control group at all follow-up assessments (p&#x02009;&#x0003c;&#x02009;0.01). (*p&#x02009;&#x0003c;&#x02009;0.05, **p&#x02009;&#x0003c;&#x02009;0.01. Independent t-test was used).</p></caption><graphic xlink:href="41598_2017_224_Fig3_HTML" id="d29e1785"/></fig>
<fig id="Fig4"><label>Figure 4</label><caption><p>Mean change from baseline in Boston Carpal Tunnel Syndrome Questionnaire (BCTQ) in both groups (mean&#x02009;&#x000b1;&#x02009;standard error). (<bold>A</bold>) PRP group had significant improvement of BCTQ (severity) compared with control group at 3<sup>rd</sup> and 6<sup>th</sup> month (p&#x02009;&#x0003c;&#x02009;0.05). (<bold>B</bold>) PRP group had significant improvement of BCTQ (function) compared with control group at all follow-up assessments (p&#x02009;&#x0003c;&#x02009;0.01). (*p&#x02009;&#x0003c;&#x02009;0.05, **p&#x02009;&#x0003c;&#x02009;0.01, ***p&#x02009;&#x0003c;&#x02009;0.001. Independent t-test was used).</p></caption><graphic xlink:href="41598_2017_224_Fig4_HTML" id="d29e1807"/></fig>
</p></sec><sec id="Sec19" sec-type="discussion"><title>Discussion</title><p>This is the first prospective, randomized, single-blind controlled trial to explore the efficacy of PRP for patients with mild-to-moderate CTS. We demonstrated that PRP significantly reduced pain severity, ameliorated disability, and improved CSA of MN 6 months post-treatment.</p><p>PRP is considered as a safe treatment and practiced in many disciplines of medicine. It is an autologous preparation utilizing the patient&#x02019;s own blood. Increasing evidence has highlighted the positive effects of PRP on peripheral nerve regeneration with acceptable safety profiles in experimental studies<sup><xref ref-type="bibr" rid="CR9">9</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref></sup>. Farrag <italic>et al</italic>.<sup><xref ref-type="bibr" rid="CR9">9</xref></sup> demonstrated beneficial effects of PRP compared with platelet poor plasma (PPP) for facial nerve regeneration in a rat model. Sariguney <italic>et al</italic>.<sup><xref ref-type="bibr" rid="CR10">10</xref></sup> showed that PRP enhanced the remyelination of the sciatic nerve in an end-to-end neurorrhaphy rat model. Ding <italic>et al</italic>.<sup><xref ref-type="bibr" rid="CR11">11</xref></sup> applied PRP to the site of bilateral nerve-crush rat model and the findings revealed a significant effect on cavernous regeneration and functional recovery. Cho <italic>et al</italic>.<sup><xref ref-type="bibr" rid="CR12">12</xref></sup> reported that PRP could promote facial nerve regeneration in a facial nerve axotomy model. Giannessi <italic>et al</italic>.<sup><xref ref-type="bibr" rid="CR13">13</xref></sup> commented that PRP could be a nerve guide to diminish scar reaction during axonal regeneration in a rat sciatic nerve model. Another study revealed that PRP could limit nerve damage 12 weeks post-injection in a rabbit model of 10% dextrose-induced MN injury (carpal tunnel model)<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>. Sanchez <italic>et al</italic>.<sup><xref ref-type="bibr" rid="CR15">15</xref></sup> found that PRP hastened functional axon recovery in an ovine model. Zheng <italic>et al</italic>.<sup><xref ref-type="bibr" rid="CR16">16</xref></sup> showed that PRP could stimulate Schwann cell proliferation, secretion of nerve growth factor, and neurotrophic factor <italic>in vitro</italic>. In contrast, Piskin <italic>et al</italic>.<sup><xref ref-type="bibr" rid="CR38">38</xref></sup> reported that PRP does not enhance axonal regeneration of peripheral nerve repair in a rat model.</p><p>The clinical benefit of PRP in peripheral neuropathy is an interesting field of research. In 2014, Anjayani <italic>et al</italic>.<sup><xref ref-type="bibr" rid="CR17">17</xref></sup> first reported a randomized, double-blind, control trial study to prove that a 1-mL PRP perineural injection could improve pain scores using a VAS, and the two-point discrimination test of peripheral neuropathy, in patients with Hansen&#x02019;s disease compared with a 1-mL PPP injection, 2 weeks after the injection of both types of plasma (n&#x02009;=&#x02009;30 vs. n&#x02009;=&#x02009;30, respectively). Subsequently, S&#x000e1;nchez <italic>et al</italic>.<sup><xref ref-type="bibr" rid="CR18">18</xref></sup> described a patient with recalcitrant peroneal nerve palsy who showed partial recovery and obvious improvement in the electrophysiological study 21 months after the first PRP injection (7 sessions of PRP injection in total). Scala <italic>et al</italic>.<sup><xref ref-type="bibr" rid="CR19">19</xref></sup> revealed that PRP has a positive effect on, and is protective against, facial nerve neurological deficits in patients undergoing superficial parotidectomy compared with a placebo group in a small randomized control trial (n&#x02009;=&#x02009;10 vs. n&#x02009;=&#x02009;10, respectively). In 2015, Malahias <italic>et al</italic>.<sup><xref ref-type="bibr" rid="CR20">20</xref></sup> first used an ultrasound-guided injection of 1&#x02013;2&#x02009;mL of PRP in patients with mild CTS (n&#x02009;=&#x02009;14, no control group) with positive mid-term outcomes (3 months). Recently, Uzun <italic>et al</italic>.<sup><xref ref-type="bibr" rid="CR21">21</xref></sup> performed a non-randomized, single-blind trial to compare the effect of PRP with steroid injection in patients with minimal to mild CTS (n&#x02009;=&#x02009;20 vs. n&#x02009;=&#x02009;20) by using blind injection. Although they showed that the PRP group had a significant improvement of BCTQ (both symptom and function scores) 3 months post-treatment compared with steroid group, the difference was not significant at the 6 month follow-up. Moreover, there was no significant change between the two groups in the electrophysiological measurements.</p><p>Even though positive effects were shown in the above clinical studies, most of these studies enrolled small patient numbers and lacked long-term follow-up. The findings of our study validate the outcomes of the above-mentioned studies. Compared with study of Uzun <italic>et al</italic>.<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>, we recruited more severe CTS (80% moderate vs. minimal to mild CTS, respectively), larger sample size (n&#x02009;=&#x02009;30 vs. n&#x02009;=&#x02009;20, respectively), and more precise injection (ultrasound-guided vs. blind injection). Moreover, the effects of PRP in our study persisted for at least 6 months, which was more obvious and lasting than the results from Uzun <italic>et al</italic>.<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>. Our study showed the most positive clinical outcomes using PRP for patients with CTS to date. Furthermore, the tendency for improvement in VAS, BCTQ, and CSA compared with the baseline or control group of our study seemed more pronounced with a longer follow-up duration (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>, Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref> and <xref rid="Fig4" ref-type="fig">4</xref>). Therefore, we believe the effect could continue for more than 6 months if the follow-up period is extended.</p><p>Although significant enhancement of FP, SNCV, and DML compared with pretreatment data was observed in both groups of the present study, the differences between the groups were not significant (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>). Moreover, any obvious tendency towards an increased difference between SNCV and DML was not seen; for example, such as FP in the PRP group compared with the control group. Uzun <italic>et al</italic>.<sup><xref ref-type="bibr" rid="CR21">21</xref></sup> revealed no significant improvement of SNCV and DML during the 6-month follow-up (except third-month SNCV) after PRP injection in patients with minimal to mild CTS in contrast with our findings. Most patients in our study diagnosed with moderate CTS may have had different results compared with those of Uzun&#x02019;s study. Moreover, different sample sizes and techniques of injection would also produce different results. Our results were compatible with Uzun&#x02019;s findings in that the improved symptoms between groups did not correlate with the improvement of electrophysiological measurements. The discordance between symptoms and electrophysiological improvement was expected because routine electrophysiological studies examine mainly large myelinated fibers rather than small sensory fibers which may be responsible for some symptoms of CTS<sup><xref ref-type="bibr" rid="CR39">39</xref></sup>. Indeed, the electrodiagnostic measurement has a limited role in predicting the therapeutic outcome for CTS after surgery and conservative treatment in previous studies<sup><xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR40">40</xref>&#x02013;<xref ref-type="bibr" rid="CR42">42</xref></sup>.</p><p>The actual mechanism underlying the effects of PRP in neuropathy is unclear. PRP has been reported to contain a variety of growth factors, including platelet-derived growth factor (PDGF), transforming growth factor-&#x003b2; (TGF-&#x003b2;), insulin-like growth factor (IGF), epidermal growth factor, fibroblast growth factor (FGF), keratinocyte growth factor, hepatocyte growth factor (HGF), nerve growth factor (NGF) and vascular endothelial growth factor<sup><xref ref-type="bibr" rid="CR43">43</xref>&#x02013;<xref ref-type="bibr" rid="CR45">45</xref></sup>. These growth factors have been suggested to play a positive role in the regeneration of injured peripheral nerves<sup><xref ref-type="bibr" rid="CR45">45</xref>&#x02013;<xref ref-type="bibr" rid="CR49">49</xref></sup>. Chen <italic>et al</italic>.<sup><xref ref-type="bibr" rid="CR46">46</xref></sup> suggested that FGF facilitates angiogenesis and acts as a neurotrophic agent during facial nerve regeneration in the pig model. Oya <italic>et al</italic>.<sup><xref ref-type="bibr" rid="CR47">47</xref></sup> revealed that PDGF-&#x003b2; is a Schwann cell mitogen and survival factor in the nerve crush-injured rat. Increased PDGF-&#x003b2; level after nerve injury might aid peripheral nerve regeneration. TGF promoted neuron survival<sup><xref ref-type="bibr" rid="CR48">48</xref></sup> and IGF particularly enhanced the growth of corticospinal motor neurons axons <italic>in vitro</italic>
<sup><xref ref-type="bibr" rid="CR49">49</xref></sup>. Moreover, HGF and NGF have also been shown to enhance axonal sprouting<sup><xref ref-type="bibr" rid="CR45">45</xref></sup>.</p><p>Hydrodissection via PRP injection could have contributed to the effect of PRP on CTS in our study. Decreased blood flow to the MN due to progressive compression of the MN is the major mechanism for CTS<sup><xref ref-type="bibr" rid="CR50">50</xref></sup>. Perineural hydrodissection around the entrapped nerve would probably potentiate ischemic damage to a nerve by peeling the MN from surrounding tissues (flexor retinaculum and connective tissue-related compression and adhesion)<sup><xref ref-type="bibr" rid="CR51">51</xref></sup>. Although the effect-duration of hydrodissection on the entrapped nerve is currently unknown<sup><xref ref-type="bibr" rid="CR51">51</xref></sup>, we believe the true effect of one dose of hydrodissection may not significantly persist because the injectate would be absorbed rapidly. Indeed, in our clinical practice, the injectate seems to be clearly absorbed one hour later after injection when rechecked by the ultrasonography. More randomized double-blind trials are necessary to examine the effects of hydrodissection in the future.</p><p>Although the mechanism of PRP in CTS in the present study are uncertain and probably multifactorial, we could hypothesize possible causes based on the significantly reduced CSA of the MN and improved electrophysiological studies. First, the PRP could promote angiogenesis, neurogenesis, and regeneration via direct effects on the MN itself based on previous experimental studies<sup><xref ref-type="bibr" rid="CR9">9</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref></sup>. Second, PRP could reduce the inflammation and swelling of the flexor tenosynovitis<sup><xref ref-type="bibr" rid="CR52">52</xref></sup> since we performed perineural injection without intraneural injection to prevent direct nerve trauma. Therefore, the PRP could diffusely encase the MN and surrounding soft tissues. The decreased swelling of the flexor tendon would result in reduction of intracarpal pressure exerted on the MN<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>. Finally, the hydrodissection could also contribute some benefits. A CTS animal model with histological studies is needed to explore and differentiate the above mechanism in the future.</p><p>There were some limitations in this study. First, the mechanism of PRP was not evaluated in this study. Second, the effect of hydrodissection and placebo from injection in our study cannot be completely excluded. However, a sham-controlled treatment or an active non-PRP injection in the control group was unfeasible and unacceptable in our country because of the invasive procedure of the PRP preparation and injection. Nonetheless, the lack of a sham-control or placebo effect can hardly explain the marked effect of PRP that lasted throughout the 6 months. Further prospective clinical trials are encouraged with sham-controlled treatment. Finally, more studies with multiple strategies are necessary to optimize the dosage regimen of PRP for optimal effects.</p><p>In conclusion, this study shows that ultrasound-guided PRP injection is safe and effective for treating CTS. The efficacy of PRP for CTS seems to be a potentially worthwhile area for further study in peripheral neuropathy.</p></sec></body><back><fn-group><fn><p>
<bold>Publisher's note:</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The study is supported by the Ministry of Science and Technology, Taiwan, Republic of China (grant no. MOST 105-2314-B-016-046). The authors are grateful to Miss Jenifert Hsu who contributed to the technical assistant and enabled the completion of this study.</p></ack><notes notes-type="author-contribution"><title>Author Contributions</title><p>Wu Y.T.: Design the study, conduct of the study, data collection, data analysis, and manuscript preparation. Ho T.Y.: Helped data analysis, conduct of the study, and manuscript preparation. Chou Y.C.: Helped conduct of the study and data analysis. Ke M.J.: Helped data analysis, conduct of the study. Li T.Y.: Recruit patients and prepared figures. Huang G.S.: Critically reviewed the manuscript. Chen L.C.: Design the study, conduct of the study, data collection, data analysis, and manuscript preparation.</p></notes><notes notes-type="COI-statement"><sec id="FPar1"><title>Competing Interests</title><p>The authors declare that they have no competing interests.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Werner</surname><given-names>RA</given-names></name><name><surname>Andary</surname><given-names>M</given-names></name></person-group><article-title>Carpal tunnel syndrome: Pathophysiology and clinical neurophysiology</article-title><source>Clin Neurophysiol</source><year>2002</year><volume>113</volume><fpage>1373</fpage><lpage>1381</lpage><pub-id pub-id-type="doi">10.1016/S1388-2457(02)00169-4</pub-id><pub-id pub-id-type="pmid">12169318</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karadas</surname><given-names>O</given-names></name><name><surname>Tok</surname><given-names>F</given-names></name><name><surname>Ula&#x0015f;</surname><given-names>UH</given-names></name><name><surname>Odaba&#x0015f;i</surname><given-names>Z</given-names></name></person-group><article-title>The effectiveness of triamcinolone acetonide vs. procaine hydrochloride injection in the management of carpal tunnel syndrome: a double-blind randomized clinical trial</article-title><source>Am J Phys Med Rehabil</source><year>2011</year><volume>90</volume><fpage>287</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1097/PHM.0b013e31820639ec</pub-id><pub-id pub-id-type="pmid">21273900</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">O&#x02019;Connor, D., Marshall, S. &#x00026; Massy-Westropp, N. Non-surgical treatment (other than steroid injection) for carpal tunnel syndrome. Cochrane Database Syst Rev. CD003219 (2003).</mixed-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katz</surname><given-names>JN</given-names></name><etal/></person-group><article-title>Maine carpal tunnel study: Outcomes of operative and nonoperative therapy for carpal tunnel syndrome in a community-based cohort</article-title><source>J Hand Surg Am</source><year>1998</year><volume>23</volume><fpage>697</fpage><lpage>710</lpage><pub-id pub-id-type="doi">10.1016/S0363-5023(98)80058-0</pub-id><pub-id pub-id-type="pmid">9708386</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerritsen</surname><given-names>AA</given-names></name><etal/></person-group><article-title>Splinting for carpal tunnel syndrome: Prognostic indicators of success</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2003</year><volume>74</volume><fpage>1342</fpage><lpage>1344</lpage><pub-id pub-id-type="doi">10.1136/jnnp.74.9.1342</pub-id><pub-id pub-id-type="pmid">12933954</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huisstede</surname><given-names>BM</given-names></name><etal/></person-group><article-title>Carpal tunnel syndrome. Part i: Effectiveness of nonsurgical treatments&#x02013;a systematic review</article-title><source>Arch Phys Med Rehabil</source><year>2010</year><volume>91</volume><fpage>981</fpage><lpage>1004</lpage><pub-id pub-id-type="doi">10.1016/j.apmr.2010.03.022</pub-id><pub-id pub-id-type="pmid">20599038</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahcan</surname><given-names>U</given-names></name><name><surname>Arnez</surname><given-names>ZM</given-names></name><name><surname>Bajrovic</surname><given-names>F</given-names></name><name><surname>Zorman</surname><given-names>P</given-names></name></person-group><article-title>Surgical technique to reduce scar discomfort after carpal tunnel surgery</article-title><source>J Hand Surg Am</source><year>2002</year><volume>27</volume><fpage>821</fpage><lpage>827</lpage><pub-id pub-id-type="doi">10.1053/jhsu.2002.35083</pub-id><pub-id pub-id-type="pmid">12239671</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sampson</surname><given-names>S</given-names></name><name><surname>Gerhardt</surname><given-names>M</given-names></name><name><surname>Mandelbaum</surname><given-names>B</given-names></name></person-group><article-title>Platelet rich plasma injection grafts for musculoskeletal injuries: A review</article-title><source>Current reviews in musculoskeletal medicine</source><year>2008</year><volume>1</volume><fpage>165</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1007/s12178-008-9032-5</pub-id><pub-id pub-id-type="pmid">19468902</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farrag</surname><given-names>TY</given-names></name><name><surname>Lehar</surname><given-names>M</given-names></name><name><surname>Verhaegen</surname><given-names>P</given-names></name><name><surname>Carson</surname><given-names>KA</given-names></name><name><surname>Byrne</surname><given-names>PJ</given-names></name></person-group><article-title>Effect of platelet rich plasma and fibrin sealant on facial nerve regeneration in a rat model</article-title><source>The Laryngoscope</source><year>2007</year><volume>117</volume><fpage>157</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1097/01.mlg.0000249726.98801.77</pub-id><pub-id pub-id-type="pmid">17202946</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sariguney</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Effect of platelet-rich plasma on peripheral nerve regeneration</article-title><source>Journal of reconstructive microsurgery</source><year>2008</year><volume>24</volume><fpage>159</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.1055/s-2008-1076752</pub-id><pub-id pub-id-type="pmid">18452111</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>XG</given-names></name><etal/></person-group><article-title>The effect of platelet-rich plasma on cavernous nerve regeneration in a rat model</article-title><source>Asian journal of andrology</source><year>2009</year><volume>11</volume><fpage>215</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1038/aja.2008.37</pub-id><pub-id pub-id-type="pmid">19151738</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>HH</given-names></name><etal/></person-group><article-title>Effect of neural-induced mesenchymal stem cells and platelet-rich plasma on facial nerve regeneration in an acute nerve injury model</article-title><source>The Laryngoscope</source><year>2010</year><volume>120</volume><fpage>907</fpage><lpage>913</lpage><pub-id pub-id-type="doi">10.1002/lary.20928</pub-id><pub-id pub-id-type="pmid">20422684</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giannessi</surname><given-names>E</given-names></name><etal/></person-group><article-title>An autologously generated platelet-rich plasma suturable membrane may enhance peripheral nerve regeneration after neurorraphy in an acute injury model of sciatic nerve neurotmesis</article-title><source>Journal of reconstructive microsurgery</source><year>2014</year><volume>30</volume><fpage>617</fpage><lpage>626</lpage><pub-id pub-id-type="doi">10.1055/s-0034-1372483</pub-id><pub-id pub-id-type="pmid">24838385</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>GY</given-names></name><name><surname>Kwon</surname><given-names>DR</given-names></name></person-group><article-title>Platelet-rich plasma limits the nerve injury caused by 10% dextrose in the rabbit median nerve</article-title><source>Muscle &#x00026; nerve</source><year>2014</year><volume>49</volume><fpage>56</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1002/mus.23863</pub-id><pub-id pub-id-type="pmid">23558771</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="other">Sanchez, M. <italic>et al</italic>. Ultrasound-guided plasma rich in growth factors injections and scaffolds hasten motor nerve functional recovery in an ovine model of nerve crush injury. J Tissue Eng Regen Med. [Epub ahead of print] (2015).</mixed-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>C</given-names></name><etal/></person-group><article-title>Effect of platelet-rich plasma (PRP) concentration on proliferation, neurotrophic function and migration of Schwann cells <italic>in vitro</italic></article-title><source>J Tissue Eng Regen Med</source><year>2016</year><volume>10</volume><fpage>428</fpage><lpage>636</lpage><pub-id pub-id-type="doi">10.1002/term.1756</pub-id><pub-id pub-id-type="pmid">23723151</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anjayani</surname><given-names>S</given-names></name><etal/></person-group><article-title>Sensory improvement of leprosy peripheral neuropathy in patients treated with perineural injection of platelet-rich plasma</article-title><source>International journal of dermatology</source><year>2014</year><volume>53</volume><fpage>109</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1111/ijd.12162</pub-id><pub-id pub-id-type="pmid">24168291</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanchez</surname><given-names>M</given-names></name><name><surname>Yoshioka</surname><given-names>T</given-names></name><name><surname>Ortega</surname><given-names>M</given-names></name><name><surname>Delgado</surname><given-names>D</given-names></name><name><surname>Anitua</surname><given-names>E</given-names></name></person-group><article-title>Ultrasound-guided platelet-rich plasma injections for the treatment of common peroneal nerve palsy associated with multiple ligament injuries of the knee</article-title><source>Knee surgery, sports traumatology, arthroscopy: official journal of the ESSKA</source><year>2014</year><volume>22</volume><fpage>1084</fpage><lpage>1089</lpage><pub-id pub-id-type="doi">10.1007/s00167-013-2479-y</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scala</surname><given-names>M</given-names></name><etal/></person-group><article-title>The use of platelet-rich plasma gel in patients with mixed tumour undergoing superficial parotidectomy: A randomized study</article-title><source>In vivo (Athens, Greece)</source><year>2014</year><volume>28</volume><fpage>121</fpage><lpage>124</lpage></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malahias</surname><given-names>MA</given-names></name><name><surname>Johnson</surname><given-names>EO</given-names></name><name><surname>Babis</surname><given-names>GC</given-names></name><name><surname>Nikolaou</surname><given-names>VS</given-names></name></person-group><article-title>Single injection of platelet-rich plasma as a novel treatment of carpal tunnel syndrome</article-title><source>Neural regeneration research</source><year>2015</year><volume>10</volume><fpage>1856</fpage><lpage>1859</lpage><pub-id pub-id-type="doi">10.4103/1673-5374.165322</pub-id><pub-id pub-id-type="pmid">26807124</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uzun</surname><given-names>H</given-names></name><name><surname>Bitik</surname><given-names>O</given-names></name><name><surname>Uzun</surname><given-names>&#x000d6;</given-names></name><name><surname>Ersoy</surname><given-names>US</given-names></name><name><surname>Akta&#x0015f;</surname><given-names>E</given-names></name></person-group><article-title>Platelet-rich plasma versus corticosteroid injections for carpal tunnel syndrome</article-title><source>J Plast Surg Hand Surg</source><year>2016</year><volume>6</volume><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1080/2000656X.2016.1260025</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moher</surname><given-names>D</given-names></name><etal/></person-group><article-title>CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials</article-title><source>BMJ</source><year>2010</year><volume>340</volume><fpage>c869</fpage><pub-id pub-id-type="doi">10.1136/bmj.c869</pub-id><pub-id pub-id-type="pmid">20332511</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>YT</given-names></name><etal/></person-group><article-title>Effect of radial shock wave therapy for carpal tunnel syndrome: A prospective randomized, double-blind, placebo-controlled trial</article-title><source>J Orthop Res</source><year>2016</year><volume>34</volume><fpage>977</fpage><lpage>984</lpage><pub-id pub-id-type="doi">10.1002/jor.23113</pub-id><pub-id pub-id-type="pmid">26610183</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jablecki</surname><given-names>CK</given-names></name><etal/></person-group><article-title>Practice parameter: Electrodiagnostic studies in carpal tunnel syndrome. Report of the american association of electrodiagnostic medicine, american academy of neurology, and the american academy of physical medicine and rehabilitation</article-title><source>Neurology</source><year>2002</year><volume>58</volume><fpage>1589</fpage><lpage>1592</lpage><pub-id pub-id-type="doi">10.1212/WNL.58.11.1589</pub-id><pub-id pub-id-type="pmid">12058083</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>You</surname><given-names>H</given-names></name><name><surname>Simmons</surname><given-names>Z</given-names></name><name><surname>Freivalds</surname><given-names>A</given-names></name><name><surname>Kothari</surname><given-names>MJ</given-names></name><name><surname>Naidu</surname><given-names>SH</given-names></name></person-group><article-title>Relationships between clinical symptom severity scales and nerve conduction measures in carpal tunnel syndrome</article-title><source>Muscle &#x00026; nerve</source><year>1999</year><volume>22</volume><fpage>497</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-4598(199904)22:4&#x0003c;497::AID-MUS11&#x0003e;3.0.CO;2-T</pub-id><pub-id pub-id-type="pmid">10204785</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossi</surname><given-names>S</given-names></name><etal/></person-group><article-title>Sensory neural conduction of median nerve from digits and palm stimulation in carpal tunnel syndrome</article-title><source>Electroencephalogr Clin Neurophysiol</source><year>1994</year><volume>93</volume><fpage>330</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.1016/0168-5597(94)90120-1</pub-id><pub-id pub-id-type="pmid">7525240</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Padua</surname><given-names>L</given-names></name><name><surname>LoMonaco</surname><given-names>M</given-names></name><name><surname>Valente</surname><given-names>EM</given-names></name><name><surname>Tonali</surname><given-names>PA</given-names></name></person-group><article-title>A useful electrophysiologic parameter for diagnosis of carpal tunnel syndrome</article-title><source>Muscle &#x00026; nerve</source><year>1996</year><volume>19</volume><fpage>48</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-4598(199601)19:1&#x0003c;48::AID-MUS6&#x0003e;3.0.CO;2-8</pub-id><pub-id pub-id-type="pmid">8538669</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Padua</surname><given-names>L</given-names></name><etal/></person-group><article-title>Neurophysiological classification and sensitivity in 500 carpal tunnel syndrome hands</article-title><source>Acta Neurol Scand</source><year>1997</year><volume>96</volume><fpage>211</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0404.1997.tb00271.x</pub-id><pub-id pub-id-type="pmid">9325471</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Napolitano</surname><given-names>M</given-names></name><etal/></person-group><article-title>Autologous platelet gel for tissue regeneration in degenerative disorders of the knee</article-title><source>Blood transfusion&#x02009;=&#x02009;Trasfusione del sangue</source><year>2012</year><volume>10</volume><fpage>72</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">22044954</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>SM</given-names></name><name><surname>Griffith</surname><given-names>JF</given-names></name><name><surname>Hui</surname><given-names>AC</given-names></name><name><surname>Tang</surname><given-names>A</given-names></name><name><surname>Wong</surname><given-names>KS</given-names></name></person-group><article-title>Discriminatory sonographic criteria for the diagnosis of carpal tunnel syndrome</article-title><source>Arthritis Rheum</source><year>2002</year><volume>46</volume><fpage>1914</fpage><lpage>1921</lpage><pub-id pub-id-type="doi">10.1002/art.10385</pub-id><pub-id pub-id-type="pmid">12124876</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>YT</given-names></name><etal/></person-group><article-title>Ultrasound-guided pulsed radiofrequency stimulation of the suprascapular nerve for adhesive capsulitis: A prospective, randomized, controlled trial</article-title><source>Anesth Analg</source><year>2014</year><volume>119</volume><fpage>686</fpage><lpage>692</lpage><pub-id pub-id-type="doi">10.1213/ANE.0000000000000354</pub-id><pub-id pub-id-type="pmid">25010824</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JY</given-names></name><name><surname>Park</surname><given-names>Y</given-names></name><name><surname>Park</surname><given-names>KD</given-names></name><name><surname>Lee</surname><given-names>JK</given-names></name><name><surname>Lim</surname><given-names>OK</given-names></name></person-group><article-title>Effectiveness of ultrasound-guided carpal tunnel injection using in-plane ulnar approach: A prospective, randomized, single-blinded study</article-title><source>Medicine</source><year>2014</year><volume>93</volume><fpage>e350</fpage><pub-id pub-id-type="doi">10.1097/MD.0000000000000350</pub-id><pub-id pub-id-type="pmid">25546691</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huskisson</surname><given-names>EC</given-names></name></person-group><article-title>Measurement of pain</article-title><source>Lancet</source><year>1974</year><volume>2</volume><fpage>1127</fpage><lpage>1131</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(74)90884-8</pub-id><pub-id pub-id-type="pmid">4139420</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levine</surname><given-names>DW</given-names></name><etal/></person-group><article-title>A self-administered questionnaire for the assessment of severity of symptoms and functional status in carpal tunnel syndrome</article-title><source>J Bone Joint Surg Am</source><year>1993</year><volume>75</volume><fpage>1585</fpage><lpage>1592</lpage><pub-id pub-id-type="doi">10.2106/00004623-199311000-00002</pub-id><pub-id pub-id-type="pmid">8245050</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jablecki</surname><given-names>CK</given-names></name><name><surname>Andary</surname><given-names>MT</given-names></name><name><surname>So</surname><given-names>YT</given-names></name><name><surname>Wilkins</surname><given-names>DE</given-names></name><name><surname>Williams</surname><given-names>FH</given-names></name></person-group><article-title>Literature review of the usefulness of nerve conduction studies and electromyography for the evaluation of patients with carpal tunnel syndrome. Aaem quality assurance committee</article-title><source>Muscle &#x00026; nerve</source><year>1993</year><volume>16</volume><fpage>1392</fpage><lpage>1414</lpage><pub-id pub-id-type="doi">10.1002/mus.880161219</pub-id><pub-id pub-id-type="pmid">8232399</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stegink Jansen</surname><given-names>CW</given-names></name><name><surname>Simper</surname><given-names>VK</given-names></name><name><surname>Stuart</surname><given-names>HG</given-names></name><name><surname>Pinkerton</surname><given-names>HM</given-names><suffix>Jr.</suffix></name></person-group><article-title>Measurement of maximum voluntary pinch strength: Effects of forearm position and outcome score</article-title><source>J Hand Ther</source><year>2003</year><volume>16</volume><fpage>326</fpage><lpage>336</lpage><pub-id pub-id-type="doi">10.1197/S0894-1130(03)00159-5</pub-id><pub-id pub-id-type="pmid">14605651</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faul</surname><given-names>F</given-names></name><name><surname>Erdfelder</surname><given-names>E</given-names></name><name><surname>Lang</surname><given-names>AG</given-names></name><name><surname>Buchner</surname><given-names>A</given-names></name></person-group><article-title>G* power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences</article-title><source>Behavior research methods</source><year>2007</year><volume>39</volume><fpage>175</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.3758/BF03193146</pub-id><pub-id pub-id-type="pmid">17695343</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piskin</surname><given-names>A</given-names></name><etal/></person-group><article-title>Platelet gel does not improve peripheral nerve regeneration: an electrophysiological, stereological, and electron microscopic study</article-title><source>Microsurgery</source><year>2009</year><volume>29</volume><fpage>144</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1002/micr.20599</pub-id><pub-id pub-id-type="pmid">19031394</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soyupek</surname><given-names>F</given-names></name><etal/></person-group><article-title>Determining the effectiveness of various treatment modalities in carpal tunnel syndrome by ultrasonography and comparing ultrasonographic findings with other outcomes</article-title><source>Rheumatol Int</source><year>2012</year><volume>32</volume><fpage>3229</fpage><lpage>3234</lpage><pub-id pub-id-type="doi">10.1007/s00296-011-2173-7</pub-id><pub-id pub-id-type="pmid">22038192</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Unglaub</surname><given-names>F</given-names></name><name><surname>Wolf</surname><given-names>E</given-names></name><name><surname>Goldbach</surname><given-names>C</given-names></name><name><surname>Hahn</surname><given-names>P</given-names></name><name><surname>Kroeber</surname><given-names>MW</given-names></name></person-group><article-title>Subjective and functional outcome after revision surgery in carpal tunnel syndrome</article-title><source>Arch Orthop Trauma Surg</source><year>2008</year><volume>128</volume><fpage>931</fpage><lpage>936</lpage><pub-id pub-id-type="doi">10.1007/s00402-007-0451-3</pub-id><pub-id pub-id-type="pmid">17874323</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manente</surname><given-names>G</given-names></name><etal/></person-group><article-title>An innovative hand brace for carpal tunnel syndrome: a randomized controlled trial</article-title><source>Muscle Nerve</source><year>2001</year><volume>24</volume><fpage>1020</fpage><lpage>1025</lpage><pub-id pub-id-type="doi">10.1002/mus.1105</pub-id><pub-id pub-id-type="pmid">11439376</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>LC</given-names></name><etal/></person-group><article-title>Ultrasound-Guided Pulsed Radiofrequency for Carpal Tunnel Syndrome: A Single-Blinded Randomized Controlled Study</article-title><source>PLoS One</source><year>2015</year><volume>10</volume><fpage>e0129918</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0129918</pub-id><pub-id pub-id-type="pmid">26067628</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eppley</surname><given-names>BL</given-names></name><name><surname>Woodell</surname><given-names>JE</given-names></name><name><surname>Higgins</surname><given-names>J</given-names></name></person-group><article-title>Platelet quantification and growth factor analysis from platelet-rich plasma: Implications for wound healing</article-title><source>Plastic and reconstructive surgery</source><year>2004</year><volume>114</volume><fpage>1502</fpage><lpage>1508</lpage><pub-id pub-id-type="doi">10.1097/01.PRS.0000138251.07040.51</pub-id><pub-id pub-id-type="pmid">15509939</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nikolidakis</surname><given-names>D</given-names></name><name><surname>Jansen</surname><given-names>JA</given-names></name></person-group><article-title>The biology of platelet-rich plasma and its application in oral surgery: Literature review. Tissue engineering</article-title><source>Part B, Reviews</source><year>2008</year><volume>14</volume><fpage>249</fpage><lpage>258</lpage></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanchez</surname><given-names>M</given-names></name><etal/></person-group><article-title>Platelet-rich plasma, a source of autologous growth factors and biomimetic scaffold for peripheral nerve regeneration</article-title><source>Expert Opin Biol Ther</source><year>2016</year><volume>28</volume><fpage>1</fpage><lpage>16</lpage></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>YS</given-names></name><etal/></person-group><article-title>Effects of basic fibroblast growth factor (bfgf)-neutralizing antibody and platelet factor 4 on facial nerve regeneration</article-title><source>Experimental neurology</source><year>1999</year><volume>155</volume><fpage>274</fpage><lpage>283</lpage><pub-id pub-id-type="doi">10.1006/exnr.1998.6980</pub-id><pub-id pub-id-type="pmid">10072303</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oya</surname><given-names>T</given-names></name><etal/></person-group><article-title>Platelet-derived growth factor-b expression induced after rat peripheral nerve injuries</article-title><source>Glia</source><year>2002</year><volume>38</volume><fpage>303</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1002/glia.10074</pub-id><pub-id pub-id-type="pmid">12007143</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McTigue</surname><given-names>DM</given-names></name><name><surname>Popovich</surname><given-names>PG</given-names></name><name><surname>Morgan</surname><given-names>TE</given-names></name><name><surname>Stokes</surname><given-names>BT</given-names></name></person-group><article-title>Localization of transforming growth factor-beta1 and receptor mrna after experimental spinal cord injury</article-title><source>Experimental neurology</source><year>2000</year><volume>163</volume><fpage>220</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1006/exnr.2000.7372</pub-id><pub-id pub-id-type="pmid">10785461</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozdinler</surname><given-names>PH</given-names></name><name><surname>Macklis</surname><given-names>JD</given-names></name></person-group><article-title>Igf-i specifically enhances axon outgrowth of corticospinal motor neurons</article-title><source>Nature neuroscience</source><year>2006</year><volume>9</volume><fpage>1371</fpage><lpage>1381</lpage><pub-id pub-id-type="doi">10.1038/nn1789</pub-id><pub-id pub-id-type="pmid">17057708</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>KD</given-names></name><name><surname>Roll</surname><given-names>SC</given-names></name><name><surname>Volz</surname><given-names>KR</given-names></name><name><surname>Freimer</surname><given-names>M</given-names></name></person-group><article-title>Relationship between intraneural vascular flow measured with sonography and carpal tunnel syndrome diagnosis based on electrodiagnostic testing</article-title><source>J Ultrasound Med</source><year>2012</year><volume>31</volume><fpage>729</fpage><lpage>736</lpage><pub-id pub-id-type="doi">10.7863/jum.2012.31.5.729</pub-id><pub-id pub-id-type="pmid">22535720</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cass</surname><given-names>SP</given-names></name></person-group><article-title>Ultrasound-Guided Nerve Hydrodissection: What is it? A Review of the Literature</article-title><source>Curr Sports Med Rep</source><year>2016</year><volume>15</volume><fpage>20</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1249/JSR.0000000000000226</pub-id><pub-id pub-id-type="pmid">26745165</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><mixed-citation publication-type="other">Takamura, M., Yasuda, T., Nakano, A., Shima, H. &#x00026; Neo, M. The effect of platelet-rich plasma on Achilles tendon healing in a rabbit model. Acta Orthop Traumatol Turc. [Epub ahead of print] (2016).</mixed-citation></ref></ref-list></back></article>